ONWARD Medical N.V. (Euronext: ONWD), the medical technology
company creating innovative spinal cord stimulation therapies to
restore movement, function, and independence in people with spinal
cord injury (SCI), today announces that it will host a webcast to
discuss its Half-Year 2024 business highlights.
The webcast will be held on September 10, 2024,
at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver
who will discuss highlights from 1H 2024 and provide a business
update.
To join the webcast via Zoom, please register
using this link.
Participants may also join by phone:
+32 2 290 9360 (Belgium)
+33 1 7095 0350 (France)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 0156 (Switzerland)
+44 203 481 5240 (United Kingdom)
+1 346 248 7799 (US)
Additional telephone numbers available
Meeting ID: 834 0031 2222
A recording of the webcast will be available on
the Company’s website following the live event.
To learn more about ONWARD Medical’s commitment
to partnering with the SCI Community to develop innovative
solutions for restoring movement, function, and independence after
spinal cord injury, please visit ONWD.com.
*All ONWARD® Medical devices and therapies, including but not
limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or
in combination with a brain-computer interface (BCI), are
investigational and not available for commercial use.
About ONWARD Medical
ONWARD® Medical is a medical technology company creating
therapies to restore movement, function, and independence in people
with spinal cord injury (SCI) and movement disabilities. Building
on more than a decade of scientific discovery, preclinical, and
clinical research conducted at leading hospitals, rehabilitation
clinics, and neuroscience laboratories, the Company has developed
ARC Therapy™, which has been awarded ten Breakthrough Device
Designations from the US Food and Drug Administration (FDA).
ONWARD ARC Therapy is targeted, programmed spinal cord
stimulation designed to be delivered by the Company’s
external ARC-EX® or implantable ARC-IM® platforms.
ARC Therapy can also be delivered by the Company’s ARC-BCI™
platform, which pairs the ARC-IM System with brain-computer
interface (BCI) technology to restore movement after SCI with
thought-driven control.
Use of non-invasive ARC-EX Therapy significantly improved upper
limb function after SCI in the global pivotal Up-LIFT trial, with
results published by Nature Medicine in May 2024. The
Company has submitted its regulatory application to the FDA for
clearance of the ARC-EX System in the US and is preparing for
regulatory submission in Europe. In parallel, the Company is
conducting clinical studies with its ARC-IM Therapy, which
demonstrated positive interim clinical outcomes for improved blood
pressure regulation following SCI. Other ongoing clinical studies
focus on using ARC-IM Therapy to address mobility after SCI and
gait challenges in Parkinson’s disease as well as using the ARC-BCI
platform to restore thought-driven movement of both upper and lower
limbs after SCI.
Headquartered in Eindhoven, the Netherlands, ONWARD Medical has
a Science and Engineering Center in Lausanne, Switzerland and a US
office in Boston, Massachusetts. The Company is listed on Euronext
Brussels and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com, and connect with us on
LinkedIn and YouTube.
For Media Inquiries: Aditi Roy, VP
Communications media@onwd.com
For Investor Inquiries: Amori Fraser, Finance
Directorinvestors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release
are forward-looking, which reflect the Company’s or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve several risks, uncertainties, and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition, and technology, can cause actual
events, performance, or results to differ significantly from any
anticipated development. Forward-looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions, or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release. All ONWARD Medical devices and therapies referenced
here, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™ and
ARC Therapy™, are investigational and not available for commercial
use.
Onward Opportunities (LSE:ONWD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Onward Opportunities (LSE:ONWD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024